J Neurol Neurosurg Psychiatry 82:e2 doi:10.1136/jnnp-2011-300504.11
  • British Neuropsychiatry Association 24th AGM, 10/11 February 2011, Institute of Child Health, Central London
  • AGM abstracts

AG.04 Parkinson's disease and Lewy body disease: the same or different?

  1. I McKeith

    Ian McKeith is Clinical Professor of Old Age Psychiatry at the Institute for Ageing and Health at Newcastle University. He is an NIHR Senior Investigator and Co-Director of the UK National Dementias and Neurodegenerative Diseases Research Network (DeNDRoN). Dr McKeith established the Consortium on Dementia with Lewy Bodies which has produced internationally accepted Consensus guidelines for the clinical and pathological diagnosis of DLB. He has published over 350 peer reviewed papers and numerous other articles. In 2008 he received a lifetime achievement award from the UK Royal College of Psychiatrists.


The terms Alzheimer's disease (AD), Parkinson's disease (PD), PD dementia (PDD) and dementia with Lewy bodies (DLB) are used by clinicians to describe the pattern and chronology of clinical presentations, the discrimination of which is useful for patient diagnosis and management. The term LB disease is used by clinicians to refer to the PD/PDD/DLB spectrum and by clinicians and scientists to refer to a pathological disease process.

A series of targeted workshops on DLB and PD dementia has led to the acceptance of operationalised criteria for the clinical diagnosis of DLB and PDD that are mutually compatible and consistent with similar systems for AD and PD. Precise use of terminology and theoretical frameworks is important to ensure that these carefully agreed categorical entities are used correctly. If not, the interpretation and comparison of translational research and clinical trials in the LB disease spectrum becomes confounded. Conversely, when considered collectively using a broad spectrum model the combined categories may capture sufficient heterogeneity to render clinicopathological correlative studies more meaningful and will allow the development and trialling of disease modifying agents for LB disorders that can be interpreted more widely than is currently the case.

Formulation of pathological criteria for LB disorders has been more problematic because of the variable pattern of expression of neuropathological lesions (τ, amyloid and α-synuclein based abnormalities) which correlate only to a limited degree with clinical phenotype, disease severity and progression.

Visit the full archive of podcasts for JNNP here >>

Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of JNNP.
View free sample issue >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article